Target Selector NGS Breast Panel

Powered by Oncomine from Thermo Fisher Scientific

Next-Gen Sequencing Breast Panel Based on the Technologies of Biocept and Thermo Fisher Scientific

Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.

  • Exclusive, targeted and actionable
  • Cost effective NGS-based solution
  • Turn-around-time (7-10 days upon receipt of specimen in most cases)
  • Sensitivity: 94.1-100% (MAF ≥0.1%)
  • Raw data available for further research
  • Specimen requirements: 8 mLs of peripheral blood in CEE-SURE™ or EDTA Tube
PD-L1, PR, ER, and AR expression testing available through Target Selector™ Circulating Tumor Cell (CTC) testing.

Current Gene List

All genes in pink font are referenced in NCCN Guidelines and/or are associated with FDA-approved therapy.

Sample Reports

Order Now

Contact us to learn how Biocept can support your research and testing.

Target Selector Kits are for research use only. Not for use in diagnostic procedures.